137
Participants
Start Date
December 31, 2006
Primary Completion Date
April 30, 2010
Study Completion Date
April 30, 2010
brivanib (active)
Tablet, Oral, Brivanib 800 mg, once daily, until progression
Local Institution, Taipei
Local Institution, Tainan City
Local Institution, Quezon
Local Institution, Cebu City
Local Institution, Davao City
Local Institution, Marseille
Penn State Milton S. Hershey Medical Center, Hershey
Albert Einstein Cancer Center, Philadelphia
Christiana Care Health Services, Newark
Duke University Medical Center, Durham
University Of Miami Miller School Of Medicine, Miami
Local Institution, Rennes
Wayne State University, Detroit
Local Institution, Reims
University Of Iowa Hospitals And Clinics, Iowa City
Medical College Of Wisconsin, Milwaukee
Local Institution, Kuala Lumpur
Northwestern University Feinberg School Of Medicine, Chicago
University Of Chicago, Chicago
Saint Louis University, St Louis
Local Institution, Kampung Baharu Nilai
Univ Of Texas Southwestern, Dallas
Md Anderson Cancer Center, Houston
Harbor-Ucla Medical Center, Los Angeles
City Of Hope National Medical Center, Duarte
Local Institution, Villejuif
Local Institution, Singapore
Local Institution, Singapore
City Of Hope National Medical Center, Duarte
Harbor UCLA Medical Center, Los Angeles
The Cancer Center At Hackensack University Medical Center, Hackensack
MD Anderson Cancer Center, Houston
Local Institution, Shatin, Nt.,
Local Institution, Gyeonggi-do
Local Institution, Seoul
Local Institution, Seoul
Local Institution, Seoul
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY